Non-alcoholic fatty liver disease (NAFLD) is a prevalent and progressive liver disease, affecting approximately 25% of the global population. This article provides a comprehensive overview of NAFLD, its pathophysiology, diagnosis, and management.
NAFLD is characterized by the accumulation of excess fat in the liver, unrelated to alcohol consumption. It is closely associated with metabolic syndrome, obesity, insulin resistance, and type 2 diabetes. The disease spectrum ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma.
NAFLD is often asymptomatic and may be incidentally diagnosed during routine blood tests or imaging studies. Liver biopsy remains the gold standard for diagnosing NASH and assessing fibrosis. However, non-invasive tests like elastography and serum biomarkers are increasingly used due to their safety and convenience.
The primary management strategy for NAFLD involves lifestyle modifications, including weight loss, healthy diet, and regular exercise. Pharmacological interventions are considered for patients with NASH or significant fibrosis. Currently, Vitamin E and Pioglitazone have shown some benefits in these patients. Several new drugs targeting different pathophysiological pathways are under investigation.
Healthcare professionals play a crucial role in the early detection and management of NAFLD. They should educate patients about the importance of lifestyle changes and monitor them regularly for disease progression. Multidisciplinary approach involving hepatologists, dietitians, and endocrinologists may be beneficial in managing this complex disease.
NAFLD is a significant global health issue with potential serious outcomes. Understanding its pathophysiology, diagnosis, and management strategies is essential for healthcare professionals to effectively manage this disease and prevent its progression.
1.
Race, Geography Linked to Gaps in Prostate Cancer Care
2.
Sports for girls are frequently abandoned due to uniform issues.
3.
According to the Lancet, having cancer and VTE at the same time increases mortality risk.
4.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
5.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
1.
Hematopoietic Clonal Competition in Blood Disorders
2.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
3.
Developmental Iron Biology Beyond Infancy: Mechanisms, Clinical Implications, and Emerging Directions
4.
Next-Generation Bone Marrow Harvest Technologies
5.
Strategic Applications in Hematology in Clinical Decision-Making
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Understanding the Common Causes of Anemia
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation